<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164447</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A205-HIV</org_study_id>
    <nct_id>NCT03164447</nct_id>
  </id_info>
  <brief_title>UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients</brief_title>
  <official_title>A Multicenter, Randomized, Parallel-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy, safety, and tolerability of UB-421 in conjunction with an
      existing failing antiretroviral therapy (ART) for 2 weeks and optimized background therapy
      (OBT) for 24 weeks, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness by Viral Load Log10 Change from Baseline</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration of UB-421</measure>
    <time_frame>35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of UB-421</measure>
    <time_frame>35 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421</intervention_name>
    <description>Monoclonal antibody by IV infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized background therapy (OBT)</intervention_name>
    <description>The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 sero-positive

          -  Receiving combination antiretroviral therapy (cART) (failing regimen) for at least 8
             weeks before Screening

          -  Have a life expectancy that is &gt; 6 months

          -  Subjects agree on using birth control barrier (female or male condom) during the
             entire study period

          -  Willing and able to participate in all aspects of the study

        Exclusion Criteria:

          -  Any prior exposure to UB-421

          -  Any active infection secondary to HIV requiring acute therapy

          -  Any significant diseases (other than HIV-1 infection) or clinically significant
             findings

          -  Any immunomodulating therapy (excluding pre-medication steroid) or systemic
             chemotherapy within 4 weeks prior to the Screening Visit

          -  Any vaccination within 2 weeks prior to the first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rayla Liu</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3616</phone_ext>
    <email>rayla.liu@unitedbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Lai</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3614</phone_ext>
    <email>annie.lai@unitedbiopharma.com</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>May 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

